This study is testing a new treatment called CHM-2101 for advanced gastrointestinal (GI) cancers, including neuroendocrine tumors, colorectal cancer, and gastric cancer. CHM-2101 is a type of CAR T-cell therapy, which uses your own immune cells (T-cells) that have been specially trained to recognize and fight cancer cells that have a marker called Cadherin 17 (CDH17). The study is looking to see what dose of CHM-2101 is safe and how well it works. You might be able to join if you are between 18 and 85 years old and have one of these GI cancers that has come back or not responded to at least one standard treatment. For gastric cancer patients, your tumor must also test positive for CDH17. The study plans to enroll 135 participants, but its current recruitment status is unclear.

Study design

This is an open-label Phase 1/2 study, meaning both you and your doctors will know which treatment you are receiving. It plans to enroll 135 participants.

What's involved

You will undergo a procedure called leukapheresis to collect your blood cells for making CHM-2101. You may also receive chemotherapy before the CHM-2101 infusion.

Compensation

Not stated in the trial record.

Follow-up

Your health will be monitored for side effects and other events for up to 15 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.